1163790-66-6

Basic information

• Product Name: 4-{(S)-2-[(5-benzyloxycarbonylmethoxy-1-phenyl-1H-pyrazole-3-carbonyl)amino]-4-tert-butoxycarbonylbutyryl}piperazine-1-carboxylic acid ethyl ester
• Synonyms: 4-{(S)-2-[(5-benzyloxycarbonylmethoxy-1-phenyl-1H-pyrazole-3-carbonyl)amino]-4-tert-butoxycarbonylbutyryl}piperazine-1-carboxylic acid ethyl ester
• CAS NO: 1163790-66-6
• Molecular Weight: 677.755
• Mol File: 1163790-66-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 4-{(S)-2-[(5-benzyloxycarbonylmethoxy-1-phenyl-1H-pyrazole-3-carbonyl)amino]-4-tert-butoxycarbonylbutyryl}piperazine-1-carboxylic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-{(S)-2-[(5-benzyloxycarbonylmethoxy-1-phenyl-1H-pyrazole-3-carbonyl)amino]-4-tert-butoxycarbonylbutyryl}piperazine-1-carboxylic acid ethyl ester(1163790-66-6)
• EPA Substance Registry System: 4-{(S)-2-[(5-benzyloxycarbonylmethoxy-1-phenyl-1H-pyrazole-3-carbonyl)amino]-4-tert-butoxycarbonylbutyryl}piperazine-1-carboxylic acid ethyl ester(1163790-66-6)

Safety Data

• Hazardous Substances Data: 1163790-66-6(Hazardous Substances Data)

Upstream product

• 1163790-65-5 4-{(S)-4-tert-butoxycarbonyl-2-[(5-hydroxy-1-phenyl-1H-pyrazole-3-carbonyl)-amino]-butyryl}-piperazine-1-carboxylic acid ethyl ester 
• 710335-28-7 4-((S)-2-amino-4-tert-butoxycarbonyl-butyryl)piperazine-1-carboxylic acid ethyl ester 
• 1402596-68-2 C₂₂H₂₇N₅O₇ 
• 5437-45-6 Benzyl bromoacetate 

Downstream Products

• 1163790-67-7 4-{(S)-4-tert-butoxycarbonyl-2-[(5-carboxymethoxy-1-phenyl-1H-pyrazole-3-carbonyl)amino]butyryl}piperazine-1-carboxylic acid ethyl ester 
• 1163790-68-8 4-[(S)-2-({5-[2-((S)-2-benzyloxycarbonyl-pyrrolidin-1-yl)-2-oxoethoxy]-1-phenyl-1H-pyrazole-3-carbonyl}amino)-4-tert-butoxycarbonylbutyryl]piperazine-1-carboxylic acid ethyl ester 
• 1163790-69-9 4-[(S)-4-tert-butoxycarbonyl-2-({5-[2-((S)-2-carboxy-pyrrolidin-1-yl)-2-oxoethoxy]-1-phenyl-1H-pyrazole-3-carbonyl}amino)butyryl]piperazine-1-carboxylic acid ethyl ester 
• 1163790-93-9 C₂₈H₃₆N₆O₉ 
• 1163791-10-3 4-[(S)-2-({5-[2-((S)-2-carbamoyl-pyrrolidin-1-yl)-2-oxo-ethoxy]-1-phenyl-1H-pyrazole-3-carbonyl}-amino)-4-carboxy-butyryl]-piperazine-1-carboxylic acid ethyl ester 
• 1163790-75-7 4-{(S)-4-carboxy-2-[(5-{2-[(S)-2-(methylcarbamoyl)-pyrrolidin-1-yl]-2-oxo-ethoxy}-1-phenyl-1H-pyrazole-3-carbonyl)-amino]-butyryl}-piperazine-1-carboxylic acid ethyl ester 
• 1163790-88-2 4-{(S)-4-carboxy-2-[(5-{2-[(S)-2-(cyclobutylmethyl-carbamoyl)-pyrrolidin-1-yl]-2-oxo-ethoxy}-1-phenyl-1H-pyrazole-3-carbonyl)-amino]-butyryl}-piperazine-1-carboxylic acid ethyl ester 
• 1163791-13-6 4-[(S)-4-carboxy-2-({5-[2-((S)-2-cyclobutylcarbamoyl-azetidin-1-yl)-2-oxo-ethoxy]-1-phenyl-1H-pyrazole-3-carbonyl}-amino)-butyryl]-piperazine-1-carboxylic acid ethyl ester 
• 1163792-56-0 4-[(S)-4-carboxy-2-({5-[2-(3-cyclobutylcarbamoyl-pyrrolidin-1-yl)-2-oxo-ethoxy]-1-phenyl-1H-pyrazole-3-carbonyl}-amino)-butyryl]-piperazine-1-carboxylic acid ethyl ester 
• 1163791-16-9 4-[(S)-4-carboxy-2-({5-[2-(3-cyclobutylcarbamoyl-azetidin-1-yl)-2-oxo-ethoxy]-1-phenyl-1H-pyrazole-3-carbonyl}-amino)-butyryl]-piperazine-1-carboxylic acid ethyl ester 
• 1163790-85-9 4-{(S)-4-carboxy-2-[(5-{2-oxo-2-[(S)-2-(pyrrolidine-1-carbonyl)-pyrrolidin-1-yl]-ethoxy}-1-phenyl-1H-pyrazole-3-carbonyl)-amino]-butyryl}-piperazine-1-carboxylic acid ethyl ester 
• 1163790-86-0 4-{(S)-4-carboxy-2-[(5-{2-oxo-2-[(S)-2-(piperidine-1-carbonyl)-pyrrolidin-1-yl]-ethoxy}-1-phenyl-1H-pyrazole-3-carbonyl)-amino]-butyryl}-piperazine-1-carboxylic acid ethyl ester 
• 1163793-66-5 4-{(S)-4-carboxy-2-[(5-{2-[(S)-2-(4-methyl-1H-imidazol-2-yl)-pyrrolidin-1-yl]-2-oxo-ethoxy}-1-phenyl-1H-pyrazole-3-carbonyl)-amino]-butyryl}-piperazine-1-carboxylic acid ethyl ester 
• 1163793-61-0 4-[(S)-4-carboxy-2-({5-[2-oxo-2-((S)-2-phenyl-pyrrolidin-1-yl)-ethoxy]-1-phenyl-1H-pyrazole-3-carbonyl}-amino)-butyryl]-piperazine-1-carboxylic acid ethyl ester 

Relevant articles and documents

Identification of high-affinity P2Y12 antagonists based on a phenylpyrazole glutamic acid piperazine backbone

A series of novel, highly potent P2Y12 antagonists as inhibitors of platelet aggregation based on a phenylpyrazole glutamic acid piperazine backbone is described. Exploration of the structural requirements of the substituents by probing the str

HETEROCYCLIC PYRAZOLE-CARBOXAMIDES AS P2Y12 ANTAGONISTS

The present invention relates to compounds of the formula I, wherein R1; R2; Z; A; B; D; Q; J; V; G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong anti-aggregating effect on platelets and thus an anti-thrombotic effect and are suitable e.g. for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are reversible antagonists of the platelet ADP receptor P2Y12, and can in general be applied in conditions in which an undesired activation of the platelet ADP receptor P2Y12 is present or for the cure or prevention of which an inhibition of the platelet ADP receptor P2Y12 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.